The Role of Probiotics in Depression and Quality of Life in Patients with Irritable Bowel Syndrome.

Probiotic supplementation produced a significant reduction in depressive symptoms as measured by BDI-II scores compared to placebo in IBS patients.

• Study was a double-blind randomized controlled trial with a pre-post intervention design conducted at Dr. Cipto Mangunkusumo National General Hospital.
• A total of 70 participants were randomly assigned: intervention group (n=35) received probiotics and control group (n=35) received placebo.
• Depressive symptoms were assessed using the Beck Depression Inventory-II (BDI-II) before and after the intervention.
• The probiotic group showed a significant reduction in BDI-II scores compared to the placebo group (p<0.0001).
• Statistical analysis was performed using the Mann-Whitney test and independent t-test, with a significance level of p<0.05.

Probiotic supplementation produced significant improvements in almost all domains of the SF-36 quality of life questionnaire compared to placebo.

• Quality of life was measured using the SF-36 questionnaire before and after the intervention.
• Significant improvements were observed in physical functioning, role physical, bodily pain, general health, vitality, social functioning, emotional well-being, and mental health domains.
• All SF-36 domain improvements reached statistical significance at p<0.0001 compared to the placebo group.
• The improvements spanned both physical and mental health components of the SF-36.

IBS is a functional gastrointestinal disorder frequently accompanied by psychological disturbances such as depression and reduced quality of life.

• The study was designed to evaluate probiotic supplementation as a potential adjunct therapy to address psychological symptoms in IBS patients.
• Probiotic intervention has been studied as a potential adjunct therapy to address psychological symptoms and improve quality of life in IBS patients.
• The study used both BDI-II and SF-36 instruments to capture psychological and quality of life outcomes in this population.

Probiotic supplementation significantly reduces depressive symptoms and improves quality of life in IBS patients, supporting probiotics as an adjunct therapy in IBS management.

• Findings were drawn from a 70-participant double-blind RCT with equal allocation to probiotic and placebo groups.
• Both primary outcomes (BDI-II and SF-36) showed statistically significant differences favoring the probiotic group (p<0.0001).
• The authors conclude these findings 'support the potential of probiotics as an adjunct therapy in the comprehensive management of IBS.'